Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Dual-Action Small Molecule Targets Neuroinflammation and Neuroprotection in Multiple Sclerosis with Dr. Daniel Vitt Immunic Therapeutics TRANSCRIPT
Download PDFFeb 10, 2025
Dr. Daniel Vitt, the CEO of Immunic Therapeutics, is taking a different approach to treating autoimmune diseases, focusing on neuroprotection, gut barrier restoration, and anti-inflammatory effects. These dual-mechanism small-molecule drugs are initially developed for multiple sclerosis and inflammatory bowel diseases....
Feb 10, 2025
Dr. Daniel Vitt, the CEO of Immunic Therapeutics, is taking a different approach to treating autoimmune diseases, focusing on neuroprotection, gut barrier restoration, and anti-inflammatory effects. These dual-mechanism small-molecule drugs are initially developed for multiple sclerosis and inflammatory bowel diseases....
Strategies for Employers to Navigate the Complex Pharmaceutical Landscape with Dr. Mark Campbell RxBenefits TRANSCRIPT
Download PDFOct 30, 2024
Dr. Mark Campbell, Chief Pharmacy Officer at RxBenefits, a prescription benefit optimizer that works with self-funded employers to help them get the best clinical and economic value from their pharmacy benefit manager relationships. As the healthcare landscape has become more complex with the rise of specialty and...
Oct 30, 2024
Dr. Mark Campbell, Chief Pharmacy Officer at RxBenefits, a prescription benefit optimizer that works with self-funded employers to help them get the best clinical and economic value from their pharmacy benefit manager relationships. As the healthcare landscape has become more complex with the rise of specialty and...
Unique Fat-Inhibiting Approach Targets Multiple Pathways in Metabolic Liver Disease with David Happel Sagimet Biosciences TRANSCRIPT
Download PDFOct 18, 2024
David Happel is President and CEO of Sagimet Biosciences, a company developing drugs to treat metabolic diseases by targeting the underlying cause of fat accumulation in the liver. The drug denifanstat limits the activity of fatty acid synthase (FASN), an enzyme that regulates fat accumulation. This approach is a...